“Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Patients with newly diagnosed multiple myeloma treated with the four-drug combination of Sarclisa (isatuximab) ...

KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally ...

Multiple myeloma (MM) is the second most common hematologic malignancy with over 35,000 new individuals being affected annually in the United States and global incidence increasing sharply in recent ...

ATLANTA, Dec. 31, 2024 /PRNewswire/ -- Aprio, the 25th largest business advisory and accounting firm in the U.S., announces the strategic acquisitions of two leading accounting firms, KRD, Ltd. and ...

Clinical characteristics, survival outcomes, and prognostic factors in subcutaneous panniculitis like T-cell lymphoma: National Cancer Database analysis (2004-2018). This is an ASCO Meeting Abstract ...

We were motivated to perform a prospective study using modern carfilzomib/lenalidomide/dexamethasone (KRd) combination therapy to assess minimal residual disease (MRD ...

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).

Phase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving ...